Core Insights - Revvity Inc. reported fourth quarter 2025 adjusted earnings of $1.70 per share, a 19.7% increase year over year, exceeding the consensus estimate of $1.55 [1] - The company achieved adjusted operating income of $229 million, slightly up from $221 million a year ago, with an adjusted operating profit margin of 29.7%, down from 30.3% [1] - Total sales reached $772.06 million, reflecting a 6% increase, with 4% organic growth, surpassing the consensus of $761.29 million [1] Life Sciences Segment - Life Sciences revenue for the fourth quarter was $382 million, a 2% increase, while organic revenue remained flat compared to the previous year [2] - The growth in the Life Sciences segment was impacted by declines in academic and government demand, despite growth from pharma and biotech [3] Diagnostics Segment - Diagnostics revenue increased by 10% to $390 million, with 7% organic growth, driven by strong performance in ImmunoDX and Reproductive Health [4] - Year-over-year margin pressure was noted due to tariffs, product mix, and foreign exchange impacts [4] Guidance - For fiscal 2026, Revvity forecasts adjusted earnings of $5.35-$5.45 per share, above the consensus of $5.32, and expects sales between $2.96 billion and $2.99 billion, exceeding the consensus of $2.93 billion [5] - The guidance indicates year-over-year growth of 4%-5% and organic growth of 2%-3%, with an anticipated adjusted operating margin of 28% [5] Market Reaction - Revvity shares experienced a decline of 4.60%, trading at $103.80 at the time of publication [5]

Investment Rating - The report maintains a BUY rating for Thermo Fisher with a new target price of US$670, up from the previous target price of US$654, indicating a potential upside of 15.8% from the current price of US$578.61 [2][8]. Core Insights - Thermo Fisher reported a strong performance in 4Q25, with revenue increasing by 7.2% year-over-year, marking the fastest quarterly growth in 2025. Adjusted EPS rose by 7.7%, surpassing Bloomberg consensus estimates by 2.2% and 1.9%, respectively [1][8]. - The company expects revenue growth of 3.9% to 5.9% and adjusted EPS growth of 5.9% to 8.4% for the full year 2026, reaffirming a long-term organic revenue growth target of 3%-6% [1][8]. Summary by Sections Financial Performance - For FY25, Thermo Fisher's revenue was US$44,556 million, with a year-over-year growth of 3.9%. The adjusted net profit was US$8,643 million, reflecting a growth of 3.1% [9][14]. - The company forecasts revenue of US$46,849 million for FY26, representing a growth of 5.1%, and adjusted net profit of US$9,130 million, which is a 5.6% increase [9][14]. Market Dynamics - The pharmaceutical and biotech sectors were the strongest client segments for Thermo Fisher in 2025, achieving mid-single-digit revenue growth for the year and high-single-digit growth in 4Q25. Management noted increased confidence among pharma companies in their relationships with governments [8]. - Biotech financing showed recovery in the second half of 2025, which is expected to drive revenue growth despite a typical lag of approximately six months between funding and R&D expenditure [8]. Strategic Acquisitions - In 2025, Thermo Fisher completed significant acquisitions, including Solventum's filtration and separation business for US$4.0 billion and Sanofi's sterile fill-finish facility for US$8.9 billion. These acquisitions are anticipated to enhance the company's global leadership in bioproduction and expand its capacity in the U.S. [8][9]. - Management expects adjusted EPS to grow by 7-9% in 2026 as a result of these strategic acquisitions [8]. Service Capabilities - Thermo Fisher's CDMO segment experienced strong growth in 2025, benefiting from limited sterile fill-finish capacity globally. The acquisition of Sanofi's facility is expected to secure growing orders for production in the U.S. [8]. - The integrated Accelerator business aims to improve project execution and reduce time-to-market for innovative drugs, thereby generating significant orders through differentiated service offerings [8].

Group 1 - Danaher Corporation reported fourth-quarter results that exceeded analyst expectations, with adjusted earnings of $2.23 per share and revenue of $6.84 billion, reflecting a year-over-year revenue increase of 4.5% [1] - The company's non-GAAP core revenue increased by 2.5%, driven by strong performance in bioprocessing [1] Group 2 - For the full year 2025, Danaher achieved adjusted earnings of $7.80 per share, marking a 4.5% growth, and revenue of $24.6 billion, which is a 3.0% increase from the previous year [2] - The company generated $6.4 billion in operating cash flow and $5.3 billion in non-GAAP free cash flow [2] Group 3 - Looking ahead, Danaher anticipates low-single-digit core revenue growth in the first quarter of 2026 [3] - For the full year, the company forecasts core revenue growth of 3% to 6% and adjusted earnings between $8.35 and $8.50 per share, with the midpoint slightly above the analyst consensus of $8.42 [3]

Core Insights - Danaher Corporation reported a strong finish for 2025 with sales of $24.6 billion and a 2% core revenue growth, alongside an adjusted diluted EPS of $7.80, reflecting a 4.5% increase [3][4][7] - The company anticipates core revenue growth of 3% to 6% for 2026, with adjusted EPS guidance set between $8.35 and $8.50 [5][15] Financial Performance - For the fourth quarter, Danaher achieved sales of $6.8 billion and a 2.5% core revenue growth, with developed markets showing low single-digit growth and high-growth markets up mid-single digits [8] - Adjusted gross margin was reported at 58.2% and adjusted operating margin at 28.3%, both down 130 basis points year-over-year [9] Segment Performance - The biotechnology segment saw a core revenue increase of 6%, driven by high single-digit growth in bioprocessing [9][10] - Life sciences segment core revenue increased by 0.5%, with a modest recovery in pharma, particularly in Europe, while academic and government demand remained muted [12] - The diagnostics segment reported a 2% core revenue increase, with clinical diagnostics growing mid-single digits [13] Product Innovation - Investment in innovation led to approximately 25% year-over-year growth in new product revenue, with significant launches in bioprocessing, life sciences, and diagnostics [6][19] - The introduction of the ZenoTOF 8600 mass spectrometry system by SCIEX is noted for delivering up to 30 times increased sensitivity compared to previous platforms [2] Future Outlook - Danaher expects high single-digit growth in bioprocessing for 2026, supported by consumables, while equipment revenue is projected to improve to approximately flat for the year [16] - The company anticipates approximately $1.8 billion in respiratory revenue for 2026, assuming a typical season and stable customer testing protocols [14]

Financial Data and Key Metrics Changes - For the full year 2025, sales reached $24.6 billion, with core revenue increasing by 2% [9] - Adjusted operating profit margin was 28.2%, and adjusted diluted net earnings per share were $7.80, up 4.5% year-over-year [9] - Free cash flow generated was $5.3 billion, resulting in a free cash flow to net income conversion ratio of approximately 145% [10] Business Line Data and Key Metrics Changes - Biotechnology segment core revenue increased by 6% [16] - Bioprocessing core revenue grew high single digits, with consumables and equipment both contributing to growth [16] - Life sciences segment core revenue increased by 0.5%, with consumables experiencing a decline due to lower demand [19] - Diagnostics segment core revenue increased by 2%, with clinical diagnostics growing mid-single digits [20] Market Data and Key Metrics Changes - Core revenues in developed markets increased low single digits, with North America flat and Western Europe up mid-single digits [15] - High growth markets saw mid-single digit increases, with solid growth outside of China, offsetting a low single-digit decline in China [15] Company Strategy and Development Direction - The company aims for long-term value creation through a differentiated portfolio and the Danaher Business System [9] - Continued investment in innovation led to over 20 new product launches in biotechnology, enhancing customer capabilities [10] - The company anticipates high single-digit core revenue growth in bioprocessing for 2026, driven by strong demand for monoclonal antibodies [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about gradual end market improvements continuing into 2026, supported by a strong balance sheet [9] - The company expects core revenue growth in the range of 3%-6% for 2026, with adjusted diluted EPS guidance set at $8.35-$8.50 [23] - Management noted that the bioprocessing market is expected to grow due to robust FDA approvals and increased uptake of existing therapies [18] Other Important Information - The company has maintained a free cash flow to net income conversion ratio exceeding 100% for 34 consecutive years [10] - The company is well-positioned for M&A opportunities, with a constructive environment and strong cash flow generation [68] Q&A Session Summary Question: Can you discuss the core revenue guidance and potential upside? - Management indicated that the 3%-6% core revenue guidance reflects expectations of continued recovery in end markets, with bioprocessing expected to remain strong [31][34] Question: What is the outlook for bioprocessing and equipment orders? - The order book supports high single-digit growth for bioprocessing, with equipment orders showing sequential growth, although still below historical levels [36] Question: How is the M&A environment shaping up? - The M&A environment is seen as more constructive, with improving valuations and a strong balance sheet allowing for potential aggressive moves [68][70] Question: What are the expectations for life sciences and academic demand? - Management expects gradual improvement in life sciences, particularly in pharma, but noted that academic demand remains muted [84][85] Question: Can you elaborate on the performance of the SCIEX segment? - SCIEX experienced mid-single-digit growth, driven by innovation and improvement in the pharma end market [42][43]

Full-Year 2025 Investor Call Corning Reports Fourth-Quarter and Full-Year 2025 Financial Results January 28, 2026 Forward-Looking and Cautionary Statements The statements contained in this presentation and related comments by management that are not historical facts or information and contain words such as "will," "believe," "anticipate," "expect," "intend," "plan," "seek," "see," "would," "target," "estimate," "forecast" or similar expressions are forward-looking statements. These forward-looking statement ...

Danaher Corporation Fourth Quarter 2025 Earnings Release January 28, 2026 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those ...

Core Viewpoint - Danaher Corp's annual profit forecast aligns closely with Wall Street estimates, and the company exceeded fourth-quarter profit and revenue expectations due to improving conditions in the life sciences sector [1] Group 1: Financial Performance - Danaher reported fourth-quarter profit and revenue that surpassed market expectations, indicating strong operational performance [1] - The company's annual profit forecast is largely in line with analysts' predictions, suggesting stability in future earnings [1] Group 2: Market Conditions - Improving conditions in the life sciences sector have positively impacted Danaher's performance, reflecting broader trends in the industry [1]

Core Viewpoint - Nantong City is committed to advancing new industrialization and leveraging artificial intelligence to transform its manufacturing sector, aiming to establish itself as a modern industrial city at the forefront of technology [1][3]. Group 1: Industrial Development - During the "14th Five-Year Plan" period, Nantong added 2,233 industrial enterprises above designated size, with an average annual growth of 8.7% in industrial added value [3]. - The six key industrial clusters in Nantong surpassed a total output value of 1.3 trillion yuan, with high-tech shipbuilding and marine engineering, as well as high-end textiles, recognized as national advanced manufacturing clusters [3]. - The number of high-tech enterprises, high-tech industry output, and strategic emerging industry output have doubled compared to the end of the "13th Five-Year Plan" [3]. Group 2: Policy Initiatives - The meeting outlined the "Nantong City Action Plan for Promoting AI + Manufacturing," focusing on creating a "Smart Manufacturing City" by emphasizing key areas such as vertical models, embodied intelligence, and critical components [4]. - The "Nantong City 2026 Special Action Plan for Promoting New Industrialization" was also deployed, aiming to establish a modern industrial system rich in Jianghai characteristics by the end of the "15th Five-Year Plan" [4]. - The meeting highlighted the importance of integrating technological and industrial innovation, encouraging enterprises to increase R&D investment and establish research institutions [3][4]. Group 3: Recognition and Collaboration - The meeting recognized the top 50 manufacturing enterprises in Nantong for 2025 and released a directory of the city's characteristic advantageous industries [4]. - Nantong was designated as a national pilot city for the digital transformation of small and medium-sized enterprises, with awards presented to representative enterprises in the offshore wind power equipment industry cluster [4].

Core Thesis - Alexandria Real Estate Equities, Inc. (ARE) has recently faced significant challenges leading to a bearish outlook, primarily due to a 45% dividend cut, which has surprised many investors [2][4]. Company Overview - ARE is a prominent landlord in the life sciences sector, owning large "Mega Campuses" in innovation hubs such as Boston, San Francisco, and San Diego, and leasing to major pharmaceutical companies and biotech firms [2]. Financial Performance - As of January 13th, ARE's share price was $54.64, with trailing and forward P/E ratios of 150.89 and 16.69 respectively [1]. - The company has a strong balance sheet and high-quality assets, but its concentration in life sciences has exposed it to a structural downturn [3]. Industry Challenges - Four major headwinds affecting ARE include tightening NIH funding, declining venture capital for startups, FDA leadership turnover and delayed approvals, and government pricing pressure on drugs, all of which have strained tenant revenue prospects [3]. - There is a dramatic oversupply of lab space, which has increased 7.5 times since 2021, while demand has dropped by 60%, leading to a projected 8.5% reduction in cash flows per building by 2026 and a nearly 30% expected decline in FFO [4]. Dividend and Future Outlook - The necessity of the dividend cut is attributed to the structural pressures that fundamentally reduce future earnings power, despite core tenants remaining operational [4]. - The situation underscores the importance of evaluating industry-specific risks and the relationship between tenant health and landlord performance, even for well-managed REITs [5]. Market Position - ARE is not among the 30 most popular stocks among hedge funds, with 31 hedge fund portfolios holding ARE at the end of the third quarter, down from 33 in the previous quarter [7].